Biomarkers: Validation & Verification
Biomarker discovery requires high confidence identification of biomarker candidates with simultaneous quantitation information to indicate which proteins are changing to a statistically relevant degree in response to disease. Because of normal clinical or biological variability, candidate biomarkers identified in the discovery stage need to be validated across a large number of samples. The challenge is to develop a fast, targeted analysis method capable of analyzing as many identified candidates as possible in minimally hundreds and potentially even thousands of samples.
Related Conference of Biomarkers: Validation & Verification
October 30-31, 2025
20th World Congress on Biomarkers, Cancer Therapy & Clinical Research
Rome, Italy
April 27-28, 2026
7th Annual Congress on Biosimilars and Future Biotherapeutics
Paris, Aland Islands
June 29-30, 2026
41st International Conference on Next-Gen Biotechnology and Applications
Aix-en-Provence, France
Biomarkers: Validation & Verification Conference Speakers
Recommended Sessions
- Biomarkers & Next-Generation Sequencing
- Biomarkers based on epidemiological investigations
- Biomarkers for Cancer Diagnosis
- Biomarkers in Drug discovery and development
- Biomarkers of Cardiovascular disorders
- Discovery of new biomarkers/validation/technologies
- Entrepreneur Investments Meet
- Imaging Technologies and Diagnostic tests of Biomarkers
- Biomarkers for Early Diagnosis and Prognosis
- Biomarkers for non-cancerous diseases
- Biomarkers in Diagnosis: Challenges and Approaches
- Biomarkers in Disease Treatment
- Biomarkers in Immune-Oncology
- Biomarkers of Disorders of the Nervous System
- Biomarkers: Validation & Verification
- Clinical and Biomedical Engineering
- Clinical Research & Biomarkers
- Genomic Biomarkers in Clinical Development
Related Journals
Are you interested in
- 3D Bioprinting & Regenerative Medicine - Biotechnology- 2025 (France)
- Advancements in Biosimilar Development Technologies - Biosimilars 2026 (France)
- Advances in Genomic Biotechnology - Biotechnology 2025 (Spain)
- AI in Drug Discovery - Biotechnology- 2025 (France)
- AI in Vaccine Development - Biotechnology- 2025 (France)
- AI-Powered Precision Medicine - Biotechnology- 2025 (France)
- Artificial Intelligence and Digital Tools in Biotherapeutics - Biosimilars 2026 (France)
- Bio-Cybernetics & Smart Implants - Biotechnology- 2025 (France)
- Biobetters: The Next Generation of Biologics - Biosimilars 2026 (France)
- Bioethics in Biotechnology 5.0 - Biotechnology- 2025 (France)
- Bioinformatics & Big Data - Biotechnology- 2025 (France)
- Biomedical Biotechnology - Biotechnology 2025 (Spain)
- Biopharmaceuticals and Biosimilars - Biotechnology 2025 (Spain)
- Biosimilar Market Access and Reimbursement Policies - Biosimilars 2026 (France)
- Biosimilars in Oncology and Autoimmune Diseases - Biosimilars 2026 (France)
- Biosimilars in Rare and Orphan Diseases - Biosimilars 2026 (France)
- Biotechnology and Global Health - Biotechnology 2025 (Spain)
- Biotechnology in Agriculture - Biotechnology 2025 (Spain)
- Biotechnology in Space - Biotechnology- 2025 (France)
- Blockchain for Biotech Data Security - Biotechnology- 2025 (France)
- Brain-Computer Interfaces & Neurobiotech - Biotechnology- 2025 (France)
- Clinical Trials & Comparability Studies for Biosimilars - Biosimilars 2026 (France)
- Collaborative Models in Biosimilar Development - Biosimilars 2026 (France)
- Computational and Systems Biology - Biotechnology 2025 (Spain)
- Cost-Effectiveness and Health Economics of Biosimilars - Biosimilars 2026 (France)
- CRISPR & Beyond - Biotechnology- 2025 (France)
- Environmental Biotechnology - Biotechnology 2025 (Spain)
- Evolving Trends and Innovations in Biosimilar Development and Access - Biosimilars 2026 (France)
- Formulation and Delivery Systems for Biologics - Biosimilars 2026 (France)
- Future Biotherapeutics: Cell and Gene Therapies - Biosimilars 2026 (France)
- Future of AgriTech - Biotechnology- 2025 (France)
- Future of Monoclonal Antibodies and Fusion Proteins - Biosimilars 2026 (France)
- Future Trends in Biotechnology - Biotechnology 2025 (Spain)
- Global Trends and Challenges in Biosimilar Adoption - Biosimilars 2026 (France)
- Immunogenicity Assessment and Risk Management - Biosimilars 2026 (France)
- Industrial Biotech & Smart Biofactories - Biotechnology- 2025 (France)
- Industrial Biotechnology - Biotechnology 2025 (Spain)
- Industrial Scale-Up and Bioprocessing - Biotechnology 2025 (Spain)
- Interchangeability and Substitution Policies - Biosimilars 2026 (France)
- Manufacturing and Quality Control of Biosimilars - Biosimilars 2026 (France)
- Marine Biotechnology - Biotechnology 2025 (Spain)
- Microbial Biotechnology - Biotechnology 2025 (Spain)
- Nanotechnology in Medicine - Biotechnology- 2025 (France)
- Patient and Physician Perspectives on Biosimilar Use - Biosimilars 2026 (France)
- Personalized Nutrition & Gut Microbiome - Biotechnology- 2025 (France)
- Pharmacovigilance and Post-Marketing Surveillance - Biosimilars 2026 (France)
- Quantum Computing in Biotech - Biotechnology- 2025 (France)
- Regulatory Pathways and Global Harmonization - Biosimilars 2026 (France)
- Smart Biomanufacturing - Biotechnology- 2025 (France)
- Stem Cell and Regenerative Medicine - Biotechnology 2025 (Spain)
- Sustainable Biotech Innovations - Biotechnology- 2025 (France)
- Synthetic Biology and Bioengineering - Biotechnology 2025 (Spain)
- Synthetic Biology: Reprogramming Life - Biotechnology- 2025 (France)
- The Future of Biotech Startups - Biotechnology- 2025 (France)
- Vaccine Development and Immunotherapy - Biotechnology 2025 (Spain)